Antibacterial agent 334 

Antibacterial agent 334 is an antimicrobial peptide with in vitro activity against both Gram-negative and Gram-positive bacteria. Antibacterial agent 334 disrupts bacterial membrane integrity, induces membrane depolarization, impairs bacterial physiological processes without causing immediate bacterial lysis, and reduces the formation of Staphylococcus aureus biofilms. Antibacterial agent 334 can be used in studies related to Staphylococcus aureus infections^[1].

Antibacterial agent 334 (0.78-100 μM; 16 h) potently inhibits the growth of E. coli BW25113, P. aeruginosa ATCC 15692, S. aureus ATCC 12600, and M. luteus ATCC 7468 with an MIC of 3.12 μM, A. baumannii ATCC 15308 with an MIC of 12.5 μM, and E. faecium ATCC 19434 with an MIC of 0.78 μM^[1].
Antibacterial agent 334 (0.78-200 μM; 20 h) inhibits 100% of growth in S. aureus ATCC 6538 and clinical isolates CI_1, CI_2, CI_3, CI_4, CI_5 at concentrations ≥6.25 μM, with an MIC of 6.25 μM for all these strains^[1].
Antibacterial agent 334 (3.13 μM, 6.25 μM, 12.5 μM; 20 h) causes dose-dependent membrane damage to S. aureus ATCC 6538, with severe membrane compromise observed at 6.25 μM and 12.5 μM, and reduced damage at 3.13 μM^[1].
Antibacterial agent 334 (100-200 μM; 30 min) efficiently disrupts the membrane potential of S. aureus ATCC 12600^[1].
Antibacterial agent 334 (1.56-18.72 μM; 24 h) reduces S. aureus ATCC 6538 mature biofilm biomass by 46% at 18.72 μM and renders residual biofilm cells non-metabolically active at 12.48 μM and 18.72 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1294.64

C₆₅H₁₀₃N₁₉O₉

CCCCCCCCCC(N[C@H](C(N[C@H](C(N[C@H]1C[C@H](N(C1)C([C@@H](NC([C@@H](NC([C@@H](NC(CCCCCCCCC)=O)CC2=CNC3=C2C=CC=C3)=O)CN)=O)CCCNC(N)=N)=O)C(N[C@H](C(N)=O)CCCNC(N)=N)=O)=O)CN)=O)CC4=CNC5=C4C=CC=C5)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. D'Aniello A, et al. Targeting Staphylococcus aureus with potent de novo-designed proline-core short antimicrobial lipopeptides. Eur J Med Chem. Published online March 17, 2026.